Pilot Study Assessing Student Interest in Combined Residency Training Pathways With Radiation Oncology.

Autor:	Mattes MD; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Patel SU; Rutgers New Jersey Medical School, Newark, New Jersey., Franco I; Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts., Vapiwala N; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Deville C Jr; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
Jazyk:	angličtina
Zdroj:	Advances in radiation oncology [Adv Radiat Oncol] 2024 Feb 07; Vol. 9 (5), pp. 101467. Date of Electronic Publication: 2024 Feb 07 (Print Publication: 2024).
DOI:	10.1016/j.adro.2024.101467
Abstrakt:	Purpose: Most medical students have limited exposure to radiation oncology (RO) before deciding which specialty to choose for residency. This may limit the number and diversity of RO applicants. The purpose of this study was to determine students' views on a combined pathway program of RO with internal medicine (IM), as well as other related medical specialties, as a potential means of overcoming barriers to interest in RO and the early decision point to solo training in a highly specialized field. Methods and Materials: In July to August 2022, all 299 United States student and postgraduate year 1 members of the American Society for Radiation Oncology were sent an electronic survey assessing their views on advantages and disadvantages of a combined IM/RO training pathway, and interest in several options of combined pathway programs. Results: Eighty participants completed the survey (response rate 27%). Thirty-four (43%) were very or extremely interested in IM/RO residency (median Likert-type rating 3, IQR 2-4). The most important potential advantages of an IM/RO pathway included greater flexibility in employment options (n = 51, 64%), enhanced general medical knowledge to facilitate ambitions in other career pathways (n = 46, 58%), improved patient care (n = 43, 54%), and having a pathway for combined hematologic/oncology and RO board certification (n = 46, 58%). In comparison to IM/RO, participants were significantly more interested in a combined RO and hematology/oncology program (median Likert-type rating 5, IQR 5-5, P = .005). Among the subgroup of 26 survey participants who believed it less likely they would apply for RO residency, 18 (69%) thought an IM/RO pathway would increase their interest in RO (median Likert-type rating 4, IQR 3-5). Interest in IM/RO did not differ by gender, race, or ethnicity. Conclusions: Combined training pathways involving RO were viewed positively by survey respondents, and may be particularly appealing to those less committed to a career in RO. Further research will help guide recommendations for the creation of these programs. Competing Interests: Malcolm D. Mattes receives grant funding from the Radiation Oncology Institute and Bristol Myers Squibb Foundation, and New Jersey Health Foundation. Neha Vapiwala leadership includes ASTRO Board of Directors, Secretary/Treasurer. Curtiland Deville's leadership includes ASTRO Board of Directors, Vice Chair, Council on Health Equity, Diversity & Inclusion. Idalid Franco receives grant funding from a Diversity Supplement through the National Institutes of Health, Center to Reduce Cancer Health Disparities (NIH-3R01CA240582-01A1S1), NIH/NCI Loan Repayment Program, and Career Development Award from the Center for Diversity and Inclusion of the Brigham and Women's Hospital. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu